China Universal Asset Management Co. Ltd. Buys 4,828 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

China Universal Asset Management Co. Ltd. boosted its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 65.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,183 shares of the biotechnology company’s stock after buying an additional 4,828 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Blueprint Medicines were worth $1,127,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Triad Wealth Partners LLC bought a new position in shares of Blueprint Medicines during the second quarter valued at about $27,000. Covestor Ltd lifted its position in shares of Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after buying an additional 291 shares in the last quarter. Headlands Technologies LLC boosted its stake in shares of Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after buying an additional 342 shares during the last quarter. Natixis purchased a new stake in shares of Blueprint Medicines during the first quarter valued at approximately $73,000. Finally, CWM LLC lifted its holdings in Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares during the period.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Morgan Stanley boosted their price objective on Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. UBS Group assumed coverage on Blueprint Medicines in a research report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines in a research report on Thursday, August 1st. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Oppenheimer boosted their price objective on Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, July 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.22.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $83.40 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. Blueprint Medicines Co. has a 52-week low of $53.73 and a 52-week high of $121.90. The firm has a market cap of $5.22 billion, a price-to-earnings ratio of -17.34 and a beta of 0.58. The business’s fifty day moving average is $89.10 and its 200 day moving average is $98.49.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The company had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. During the same period in the previous year, the company posted ($2.19) EPS. The firm’s revenue for the quarter was up 139.9% compared to the same quarter last year. Research analysts predict that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Insider Activity at Blueprint Medicines

In related news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the transaction, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.